Product Details            

• Isotype Control

• Brilliant Violet 605™ Rat IgG2b, κ Isotype Ctrl

• Verified Reactivity

• Mouse, Human

• Reported Reactivity

• Chimpanzee, Baboon, Cynomolgus, Rhesus, Squirrel Monkey, Horse, Cow, Pig, Dog, Cat

• Antibody Type

• Monoclonal

• Host Species

• Rat

• Immunogen

• Dexamethasone-induced myeloid leukemia M1 cells

• Formulation

• Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

• Preparation

• The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.

• Concentration

• 0.2 mg/ml

• Storage & Handling

• The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

• Application

•                            

  FC - Quality tested

• Recommended Usage

• Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
  
  Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.

  
  Learn more about Brilliant Violet™.
  
  This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

• Excitation Laser

• Violet Laser (405 nm)
  

• Application Notes

• Clone IM7 has been reported to recognize an epitope common to alloantigens and all isoforms of CD44^17,18 that is located between amino acids 145 and 186²⁰. This clone has been verified for immunocytochemistry (ICC) and frozen immunohistochemistry (IHC-F). Additional reported applications (for the relevant formats) include: immunohistochemistry of acetone-fixed frozen sections and formalin-fixed paraffin-embedded sections^6,7, complement-mediated cytotoxicity¹, immunoprecipitation^1,3, in vivo inhibition of DTH^4,5, and spatial biology (IBEX)^23,24. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103046, 103065 - 103069).
  
  Cross-reactivity to ferret has been reported by a collaborator, but not verified in house.

• Application References
  
  (PubMed link indicates BioLegend citation)

• See More

2. Trowbridge IS, et al. 1982. Immunogenetics 15:299. (ICFC, IP, CMCD)

4. Katoh S, et al. 1994. J. Immunol. 153:3440. (ELISA)

6. Budd RC, et al. 1987. J. Immunol. 138:3120. (IP)

8. Camp RL, et al. 1993. J. Exp. Med. 178:497. (Block)

10. Weiss JM, et al. 1997. J. Cell Biol. 137:1137. (Block)

12. Frank NY, et al. 2005. Cancer Res. 65:4320. (IHC) PubMed

14. Cuff CA, et al. 2001. J. Clin. Invest. 108:1031. (IHC)

16. Lee JW, et al. 2006. Nature Immunol. 8:181.

18. Zhang N, et al. 2005. J. Immunol. 174:6967. PubMed

20. Huabiao C, et al. 2005. J. Immunol. 175:591. PubMed

22. Gui J, et al. 2007. Int. Immunol. 19:1201. PubMed

24. Wang XY, et al. 2008. Blood 111:2436. PubMed

• Product Citations

• See More

1. Fernandez HR, et al. 2018. Cell Death Differ. 25:1239. PubMed

2. Young JS, et al. 2018. Front Immunol. 9:1385. PubMed

3. Shi H et al. 2018. Immunity. 49(5):899-914 . PubMed

4. Ding L et al. 2018. Cell reports. 25(11):2972-2980 . PubMed

5. Lercher A, et al. 2019. Immunity. 51:1074. PubMed

6. Leruste A, et al. 2020. Cancer Cell. 36(6):597-612.e8.. PubMed

7. McGinley AM, et al. 2020. Immunity. 52(2):342-356. PubMed

8. Lederer K, et al. 2020. Immunity. 53(6):1281-1295.e5. PubMed

9. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed

10. Kim EH, et al. 2020. Elife. 9:00. PubMed

11. Dubois V, et al. 2021. NPJ Vaccines. 6:06. PubMed

12. Glassman CR, et al. 2021. eLife. 10:00. PubMed

• RRID

• AB_2562451                                (BioLegend Cat. No. 103047)